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Purpose: The 4p static noncoplanar radiation therapy delivery technique has demonstrated better
normal tissue sparing and dose conformity than the clinically used volumetric modulated arc
therapy (VMAT). It is unclear whether this is a fundamental limitation of VMAT delivery or the
coplanar nature of its typical clinical plans. The dosimetry and the limits of normal tissue toxicity
constrained dose escalation of coplanar VMAT, noncoplanar VMAT and 4p radiation therapy are
quantified in this study.
Methods and materials: Clinical stereotactic body radiation therapy plans for 20 liver patients
receiving 30 to 60 Gy using coplanar VMAT (cVMAT) were replanned using 3 to 4 partial
noncoplanar arcs (nVMAT) and 4p with 20 intensity modulated noncoplanar fields. The confor-
mity number, homogeneity index, 50% dose spillage volume, normal liver volume receiving >15
Gy, dose to organs at risk (OARs), and tumor control probability were compared for all 3 treatment
plans. The maximum tolerable dose yielding a normal liver normal tissue control probability <1%,
5%, and 10% was calculated with the Lyman-Kutcher-Burman model for each plan as well as the
resulting survival fractions at 1, 2, 3, and 4 years.
Results: Compared with cVMAT, the nVMAT and 4p plans reduced liver volume receiving >15
Gy by an average of 5 cm3 and 80 cm3, respectively. 4p reduced the 50% dose spillage volume by
w23% compared with both VMAT plans, and either significantly decreased or maintained OAR
doses. The 4p maximum tolerable doses and survival fractions were significantly higher than both
cVMAT and nVMAT (P < .05) for all normal liver normal tissue control probability limits used in
this study.
Conclusions: The 4p technique provides significantly better OAR sparing than both cVMAT and
nVMAT and enables more clinically relevant dose escalation for tumor local control. Therefore,
despite the current accessibility of nVMAT, it is not a viable alternative to 4p for liver SBRT.Conflicts of interest: Ke Sheng receives research grants from Varian Medical Systems.
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Liver cancer is responsible for over 600,000 deaths each
year, according to the American Cancer Society, making it
a leading cause of cancer deaths worldwide. Although
surgical resection is considered the primary treatment op-
tion for hepatocellular carcinoma and oligometastases,
80% to 90% of patients present with unresectable tumors,1
which are treated with modalities including radiation ther-
apy. Conventionally fractionated radiation therapy has
shown ineffective to achieve local control,2 but stereotactic
body radiation therapy (SBRT), with the delivery of fewer
high-dose fractions, is a more effective treatment for pa-
tients with eligible conditions,3 which typically include
inoperable liver tumors under the size of 6 cm and certain
liver function criteria.4 The success of SBRT is largely
owed to the higher biological effective doses (BED) as well
as normal tissue sparing afforded by improved dose con-
formity from recent advances in radiation physics.1,5,6
Volumetric modulated arc therapy (VMAT) is a
practical and effective delivery technique for liver SBRT,
and has demonstrated normal tissue sparing and dose
conformity superior to coplanar intensity modulated
radiation therapy (IMRT).7 Although the incorporation of
non-coplanar beams has improved normal tissue sparing
in liver IMRT studies,7-9 typical clinical VMAT liver
plans are still coplanar, consisting of a pair of (clockwise
and counterclockwise) arcs using collimators with 90
rotational offset. To gain dose conformity and liver
sparing, manually selected noncoplanar VMAT has been
clinically used, but its benefit has not been quantified.
Meanwhile, methods for the automatic selection of
noncoplanar IMRT beams and optimized fluence maps
have been developed for treatment sites including liver
SBRT. Two separate groups have shown that by opti-
mizing noncoplanar beam orientation selection, superior
dosimetry to coplanar VMAT can be attained.9,10 In this
study, we refer to the beam orientation optimized
noncoplanar IMRT plans as “4p static” because of the
maximum of 4p steradian angles that can be used for
noncoplanar beam orientation optimization. The usable
angles are typically smaller than 4p because of collision
concerns and couch pedestal occlusion.11 Because the
delivery efficiency of noncoplanar IMRT plans is
considered lower than that of VMAT without the use of
automation, a function unavailable to most clinics, 1
important question is whether manually selected nonco-
planar VMAT, which is the only clinically available
method to incorporate these arcs, can offer dosimetrysuperior to coplanar VMAT while maintaining the
advantage of clinical availability and efficiency. The
purpose of this study is therefore to quantify and compare
the dosimetry of these planning methods for liver SBRT.
Methods and Materials
Coplanar VMAT plans
Under institutional review board approval, treatment
plans including computed tomography, dose, and con-
tours were obtained for 20 liver SBRT patients (Table 1).
These patients were treated with VMAT plans (RapidArc,
Eclipse Treatment Planning System Version 10, Varian),
typically consisting of 2 full coplanar arcs (cVMAT) with
90 collimator angle offset. The few original plans that
included 1 partial noncoplanar arc were reoptimized in
Eclipse with 1 full coplanar arcs to set a uniform baseline.
Noncoplanar VMAT plans
These clinical planswere replanned in Eclipse with 3 to 4
manually selected partial noncoplanar arcs (nVMAT), as
shown in Figure 1 (middle), with collimator angle offsets
between 45 and 135. The average total arc length for the 20
nVMAT plans was 553. These arcs were empirically cho-
sen to maximize noncoplanar angles while avoiding colli-
sion. Each plan typically consisted of 1 arc with a 0 couch
rotation, 2 arcs with an average couch rotation of 21
(40 to þ35 range), and for a few patients with tumors
located near the mid-sagittal plane, 1 arc with a nearly
perpendicular couch kick (86 on average). The optimiza-
tion objectives were set up to minimize dose to liver, kid-
neys, spinal cord, and stomach, with the highest priority
placed on the normal liver dose. All plans were normalized
to deliver 100% of the prescribed dose to 95% of the plan-
ning target volume (PTV), and PTV hot spots were limited
to those of the respective coplanar plans. A source-to-axis
distance of 100 cm was maintained for all plans.
4p static plans
The first step in the 4p static optimization process, the
details of which have been previously reported,10 is to
eliminate any beams out of the 1162 beam 4p static solid
angle space that would cause collisions between the gantry
and couch or patient. From the remaining beams, an inte-
grated beam orientation and fluence map optimization
Table 1 Patient data
Diagnosis Prescription
dose (Gy)
Fractions PTV
(cm3)
Normal liver
volume (cm3)
Liver
volume (cm3)
1 Metastatic esophageal cancer 60 5 53.3 1491.0 1544.5
2 Metastatic squamous cell carcinoma 60 5 64.9 2169.9 2234.7
3 Metastatic adenocarcinoma of the lung 60 5 46.7 1194.2 1239.0
4 Metastatic colorectal cancer 60 5 35.6 1168.6 1187.5
5 Metastatic colon cancer 60 5 59.2 1404.7 1454.3
6 Metastatic colorectal cancer 50 5 123.0 1324.1 1447.1
7 Metastatic uterus carcinosarcoma 50 5 35.1 1768.8 1803.8
8 Metastatic transitional cell from the kidney 60 5 30.2 1241.2 1270.1
9 Metastatic colon cancer 50 5 179.0 1752.7 1909.4
10 Hepatocellular carcinoma 36 3 54.4 1133.4 1187.9
11 Metastatic colon cancer 60 5 88.4 1302.7 1391.1
12 Metastatic prostate adenocarcinoma 60 5 10.5 1442.7 1453.3
13 Metastatic cholangiocarcinoma 40 5 48.8 1837.0 1837.0
14 Metastatic high-grade cholangiocarcinoma 48 3 19.4 1027.0 1047.8
15 Cholangiocarcinoma 40 5 88.7 1787.0 1852.0
16 Cholangiocarcinoma 40 5 67.0 2517.6 2577.3
17 Cholangiocarcinoma 40 5 141.8 1809.6 1926.6
18 Metastatic primitive germ cell tumor 30 5 192.9 3342.8 3346.1
19 Metastatic gall bladder small-cell carcinoma 60 5 109.4 1533.5 1616.2
20 Metastatic bile duct adenocarcinoma 50 5 57.3 1107.8 1148.6
PTV, planning target volume.
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Briefly, the remaining candidate beams were subdivided
into 5 5 mm2 beamlets and the dose distribution matrices
of each beamlet were calculated using collapsed-cone
convolution/superposition codes and 6-MV x-ray poly-
energetic kernels with heterogeneity corrections. The dose
calculation model was tuned to match 6-MV machine
commissioning data. The dose calculation resolution
was 2.5  2.5  2.5 mm3. The first-order derivative of
the quadratic cost function with each additional beam from
the candidate pool was evaluated and the beam that
contributed most was kept. The process was iteratively
performed until the desired number of beams was selected.
Full fluence map optimization was performed after each
beam selection. Although the cost function value did not
converge, the dosimetric gains with more than 20 beams
were modest. Considering a balance between plan deliv-
erability and plan quality, In this study, 20 beams were
selected with the 4p static algorithm for each patient, suchFigure 1 Beam geometry comparison for a typical liver stereotactic
coplanar volumetric modulated arc therapy (VMAT) plan (left), 3 to 4
beams (right).as those in Figure 1 (right), the gantry and couch angles for
each beam were imported into Eclipse to develop a clini-
cally deliverable treatment plan using identical dose
calculation engine as the VMAT plans. The organs at risk
(OAR) constraints, plan normalization, source-to-axis dis-
tance, and PTVhotspotsmatched those described earlier for
the nVMAT plans.
Additional notes on the optimization
implementation
For each plan optimization, dose constraints were
placed on the liver, kidney, spinal cord, and stomach.
When necessary, additional optimization constraints were
placed on other OARs such as the bowel or heart,
depending on the location of the tumor. Although the
constraints and penalties were initially the same for each,
these parameters were adjusted throughout the optimiza-
tion process to further reduce OAR doses for allbody radiation therapy case. Beam orientation is shown for the
noncoplanar partial arcs (center), and 20 noncoplanar, optimized
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depend on both the sequence of the planning parameters
used along with the process and the timing of when they
are used, maintaining a single set of constraints and
penalties generally would result in poorer plan quality.
Instead, the objectives for each plan were pushed as hard
as possible to reduce OAR doses, particularly to the
normal liver, while maintaining acceptable PTV doses.
The normal tissue objective was also used, with a 0.1-cm
distance from target border, 99% start dose, 50% end
dose, and 0.2 falloff. Each plan was reoptimized until no
further OAR dose reduction could be achieved without
compromising PTV coverage (typically between 2 and 4
runs).
Plan comparison
The cVMAT, nVMAT, and 4p static plans were
evaluated by comparing various metrics of normal tissue
sparing. The minimum dose to 98% of the PTV (D98%)
was compared among the 3 plans to evaluate any under-
dosage to the target. The conformity of each plan was
evaluated by the conformity number (CN), defined by
van’t Riet et al as
CNZTVRITV  TVRIVRI ; ð1Þ
where TVRI is the target volume covered by the pre-
scription isodose, TV is the target volume, and VRI is the
volume of the prescription isodose.13 R50, defined as the
ratio of the 50% isodose volume to the PTV, was used to
evaluate the dose gradient outside the PTV. The homo-
geneity index was also calculated as 1 þ (D2% e D98%)/
(prescription dose). The normal liver volume receiving
>15 Gy (VL>15) was quantified to assess normal tissue
dose, as were the mean and maximum doses to OARs.
A radiobiological modeling study was performed to
compare the probabilities of tumor control, normal tissue
complication, and patient survival. The tumor control
probability (TCP) was first calculated for each plan.
Because TCP calculation parameters vary widely between
studies and for different tumor types,14,15 and because a
variety of tumor origins were included in this study, high
tumor radioresistance was assumed for the parameter se-
lection (aZ 0.2 Gy1, a/bZ 10 Gy) for a conservative
TCP estimate. The Kutcher-Burman dose-volume histo-
gram (DVH) reduction scheme16 was used to calculate the
normal liver effective volume, the percentage of the
normal liver volume that, if irradiated uniformly to the
prescription dose, would give the same normal tissue
complication probability (NTCP) as the nonuniform dose
distribution. The effective volume was then used to
calculate the normal liver NTCP using the Lyman
model.17 The Lyman-Kutcher-Burman (LKB) NTCP
model parameters from Dawson et al were used(TD50 Z 45.8 Gy [metastases], TD50 Z 39.8 Gy [pri-
mary tumors], n Z 0.97, m Z 0.12).18 Because these
parameters were obtained from fractionated treatment
plans, the SBRT plans in this study were normalized to
1.5 Gy per fraction using a/b Z 2.5 Gy.19
Dose escalation
The prescription dose for each plan was escalated (or
reduced) to the maximum tolerable dose (MTD) yielding
a normal liver NTCP below the desired limit. The number
of fractions for the clinical plans was maintained, with an
escalated dose per fraction. In this study, MTDs for NTCP
limits of 1%, 5%, and 10% were calculated. The BED for
each MTD was determined by
BEDZNdþ N
a=bd
2  ln2
aTd
T ð2Þ
with number of fractions N, dose per fraction d, total
treatment time T, a Z 0.01, a/b Z 15, and tumor
doubling time Td Z 120 days from Tai et al.
20 The sur-
vival model developed by Tai et al was used to predict the
survival rates (SR) for each plan based on the BED:
SRðD; d; tÞZ1 1ffiffiffiffi
2p
p
Z t
N
e
x2
2 dx ;
tZe


a

1þ d
a=b

DgTðgðtT ÞÞd

K50=K0
sk=K0
ð3Þ
where D is the prescription dose, t is the elapsed time
since treatment, d describes the tumor growth rate, K0 is
the initial number of tumor clonogens, K50 is the critical
number of tumor clonogens corresponding to death in
50% of patients, sk is the Gaussian width for the critical
clonogen number distribution, and gZ ln2/Td. The fitting
parameters from Tai et al are K50/K0 Z 2.03, sk/K0 Z
0.65, and d Z 0.2.20 Survival fractions at 1, 2, 3, and 4
years were calculated for each plan before and after dose
escalation.
Results
Plan comparison
The average dose statistics for each plan type, using
paired, 2-tailed t tests, are given in Table 2. On average,
the nVMAT plans delivered higher kidney doses than the
cVMAT plans and lower doses to the other OARs, but the
Table 2 Average dose statistics for coplanar VMAT, noncoplanar VMAT, and 4p plans for all 20 patients
Plan type OAR doses (Gy)
Left kidney (mean) Right kidney (mean) Normal liver (mean) Stomach (maximum) Cord (maximum) Body (mean)
cVMAT 1.42a (2.4) 2.04 (2.4) 7.07a (2.6) 11.15 (6.7) 6.69a (3.2) 1.51a (0.6)
nVMAT 1.46a (2.1) 2.09 (2.5) 6.97a (2.8) 10.95a (10.0) 5.74a (4.0) 1.51a (0.6)
4p 0.82 (1.2) 1.70 (1.4) 6.01 (2.3) 7.58 (6.3) 4.00 (3.7) 1.46 (0.6)
PTV D98% (Gy) VL>15 (cm
3) V50% (cm3) R50 HI CN
cVMAT 49.62a (9.6) 233.7a (120.8) 271.5b (185.6) 3.66b (0.4) 0.11 (0.03) 0.94 (0.03)
nVMAT 49.59 (9.7) 228.7a (122.3) 287.5b (213.4) 3.77a (0.5) 0.10 (0.02) 0.93 (0.04)
4p 49.42 (9.7) 153.9 (84.5) 210.8 (146.4) 2.82 (0.3) 0.11 (0.03) 0.93 (0.03)
cVMAT, coplanar volumetric modulated arc therapy; nVMAT, noncoplanar volumetric modulated arc therapy; OAR, organ at risk; PTV, planning
target volume; VL>15, volume receiving >15 Gy.
a Significantly different from 4p with P < .05 (paired, 2-tailed t test).
b Significantly different from 4p and other VMAT plan type with P < .05 (paired, 2-tailed t test).
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V50%. However, there were large improvements with 4p
static compared with both VMAT techniques. The mean
dose to the normal liver was significantly lower with the
4p static plan, and the liver volume receiving >15 Gy
was reduced from the cVMAT and nVMAT plans by
79.8 cm3 and 74.8 cm3, respectively (>32%). Although
nVMAT enabled reductions in maximum stomach and
spinal cord doses (compared with cVMAT) of approxi-
mately 2% and 14%, respectively, 4p static reduced
these doses by 32% and 40%. The homogeneity index
and CN values were similar for all plans. The individual
dosimetric parameter comparison is shown in Figure 2.
Consistent reduction in the R50 from cVMAT to 4p
static was observed for all patients and the reduction is
correlated to that of liver V15 and mean liver dose. In
comparison, R50 of nVMAT slightly increased from
cVMAT, indicating no improvement in the dose
compactness.
These reductions in OAR dose are evident in the
DVHs in Figure 3 (top). Additionally, the 4p static
technique reduced the 50% dose spillage volume by
>22% compared with both VMAT plans. The major
reduction in 50% isodose volume with the 4p static
technique is evident in the dose washes in Figure 3
(bottom). Although the dose washes show less low
dose spillage for the nVMAT plan than the cVMAT
plan, the isodose volume above 15 Gy is very similar.
There was a statistically significant difference between
the mean cVMAT and 4p static PTV D98% doses, but
only by 0.2 Gy.
The average TCP values (calculated with the LKB
model), given in Table 3, were very similar for
nVMAT and cVMAT plans and slightly (w1.1%)
lower for 4p static. Although the optimization con-
straints on the maximum PTV dose were relaxed, 4p
static plans still tend to result in more homogenous
PTV doses, as seen in the DVH in Figure 2 (top), and
slightly lower TCP.The average normal liver effective volume was very
similar for the VMAT plans, but was significantly
reduced with 4p static by >15%. The resultant NTCP
was therefore also much lower, with reductions of 69%
from cVMAT and 73% from nVMAT.
Dose escalation
The results of the dose escalation are given in Table 4.
For every NTCP limit, 4p static enabled significantly
higher averageMTDs than both cVMAT and nVMAT. The
escalated doses for 4p static were approximately 20% and
14% higher than those for cVMAT and nVMAT, respec-
tively. The corresponding BEDs for 4p static were higher
than cVMAT and nVMAT for every NTCP limit by about
39% and 19%, respectively, with a statistically significant
difference between 4p static and cVMAT at the 5% level
(paired, 2-tailed t test). The average MTD and BED for
nVMAT were higher than cVMAT for every NTCP limit,
but not statistically significant at the 5% level.
The average survival fractions at 1, 2, 3, and 4 years
for each NTCP limit (1%, 5%, and 10%) showed a
statistically significant increase for the 4p static plans
compared with both VMAT plans, as shown in Figure 4.
These improvements were most significant for the 4p
static 4-year survival fraction, which was more than 7%
higher than both VMAT plans at the 10% and 5% NTCP
limits and more than 9% higher at the 1% NTCP limit.
Even for conservative treatments allowing for only a 1%
probability of liver complications, 4p static technique
enabled an average 4-year survival fraction of 86%. This
increased to 93% when a 10% NTCP was tolerated.
Delivery time
The delivery time of 2 arc cVMAT for SBRT treat-
ment was estimated as 5 to 7 minutes. The time increased
by an additional 1 to 3 minutes for nVMAT, depending
on whether remote couch rotation was used. Delivery of
Figure 2 Individual patient dosimetric results comparison. CI, confidence interval; cVMAT, coplanar volumetric modulated arc
therapy; L, left; max, maximum; nVMAT, noncoplanar volumetric modulated arc therapy; R, right.
72 K. Woods et al Advances in Radiation Oncology: JanuaryeMarch 2016the 4p treatment with 20 beams can take 45 minutes with
manual couch rotation and translation. A significant
portion of the time was used by the therapist to enter and
exit the shielded vault. Consequently, the time can be
reduced to 12 minutes with automated delivery,11 in line
with the nVMAT delivery time.Discussion
The success of SBRT is largely attributed to the
improved physical dose conformity enabled by recent
advances in radiation therapy techniques, including
intensity modulated radiation therapy, image-guided
radiation therapy, and volumetric modulated arc therapy.A previous study showed that tumor local control can
benefit from further dose escalation,5 but is limited by
normal tissue toxicity.
Experience from intracranial radiosurgery suggests that
an effective way to achieve a steeper dose gradient
outside the tumor is by adding non-coplanar beams and
arcs.21 The usefulness of noncoplanar beams in SBRT has
been far less clear. R50 has been commonly used to
evaluate the dose compactness in SBRT treatment,22 the
minimization of which leads to more effective SBRT.23
Lung Radiation Therapy Oncology Group protocols24
recommend using either noncoplanar static or coplanar
arc beams to achieve the R50 dosimetric goal. Lim et al
25
showed that compared against coplanar plans, lower R50
could be achieved in 81% of patients when noncoplanar
Figure 3 (Top) Dose-volume histograms for a typical liver SBRT case. (Bottom) Dose color washes for each plan type. The orange
contours represent the PTV volume, and the blue represent the 50% isodose lines. cVMAT, coplanar volumetric modulated arc therapy;
nVMAT, noncoplanar volumetric modulated arc therapy; PTV, planning target volume; SBRT, stereotactic body radiation therapy.
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lung study, no dosimetric improvements were foundTable 3 Biological modeling parameter results for
cVMAT, nVMAT, and 4p plans for all 20 patients (standard
deviation in parentheses)
TCP Veff NTCP
a
cVMAT 7.37% (11.5%) 13.79%b (5.2%) 5.29% (18.8%)
nVMAT 7.40%b (11.1%) 14.00%b (5.9%) 6.22% (22.2%)
4p 6.25% (9.7%) 11.63% (4.35%) 1.65% (6.3%)
cVMAT, coplanar volumetric modulated arc therapy; NTCP, normal
tissue complication probability; nVMAT, noncoplanar volumetric
modulated arc therapy; Veff, effective volume.
a The mean NTCP is drastically increased by 2 outlying patients,
without which the mean NTCP values are 0.06%, 0.53%, and 0.02%
for cVMAT, nVMAT, and 4p, respectively.
b Significantly different from 4p plans with P < .05 (paired,
2-tailed t test).comparing coplanar and noncoplanar IMRT plans.26 In
the case of liver radiation therapy, it was found that the
advantage of using noncoplanar beams can be matched by
coplanar plans with a large number of beams.27 Nonco-
planar VMAT has been used on an ad hoc basis in liver
SBRT7 with the expectation that these arcs should
improve normal organ sparing without quantification of
the dosimetric improvement.
In this study, we compared 3 clinically deliverable
planning methods for liver SBRT. Our study shows that
the incorporation of this type of arrangement of nonco-
planar VMAT arcs offered modest dosimetric gains over
coplanar VMAT. However, by fully using the freedom of
the noncoplanar beam geometry solution space and
automated beam orientation selection, the 4p static
technique achieved major reductions in the dose to OARs,
particularly the normal liver, stomach, and spinal cord, as
well as a much more compact dose distribution.
Table 4 Dose escalation based on the normal liver effective volume and desired normal liver LKB NTCP for all 20 patients
(standard deviation in parentheses)
1% NTCP 5% NTCP 10% NTCP
MTD (Gy) BED (Gy) MTD (Gy) BED (Gy) MTD (Gy) BED (Gy)
cVMAT 76.80a (27.6) 170.40a (97.8) 85.51a (30.7) 202.70a (117.6) 90.14a (32.4) 220.94a (129.0)
nVMAT 80.63a (37.7) 198.32 (177.7) 89.76a (41.6) 236.78 (215.5) 94.65a (43.8) 258.67 (237.4)
4p 91.98 (36.2) 235.80 (164.8) 102.43 (40.3) 281.91 (199.8) 107.99 (42.5) 308.08 (219.8)
cVMAT, coplanar volumetric modulated arc therapy; NTCP, normal tissue complication probability; LKB, Lyman-Kutcher-Burman; MTD,
maximum tolerated dose; nVMAT, noncoplanar volumetric modulated arc therapy.
a Significantly different from 4p plans with P < .05 (paired, 2-tailed t test).
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improvement from nVMAT over cVMAT. First, in
practice, the number of VMAT arcs is limited. Because of
the continuity of the arcs, large noncoplanar angles are
prohibited to avoid collision. This is different from
intracranial stereotactic radiation surgery, where a large
noncoplanar beam solution space can be nearly uniformly
sampled and included. It has been shown that the inclu-
sion of small noncoplanar arc angles in a rotational IMRT
system does not significantly improve the plan quality.28
Second, selection of noncoplanar arcs is unintuitive to
the planner. It is difficult, if not impossible, for a human
operator to optimally select segments of noncoplanar arcs,
considering the freedoms of arc lengths and locations.
One way to overcome this limitation is by optimizing the
noncoplanar arc selection. However, a method to globally
search the noncoplanar arc trajectories, or “4p arc,” is un-
available. Papp et al29 reported a noncoplanar arc optimi-
zation method based on static beam orientation optimization
and then use these beams to anchor noncoplanar segments.
However, this method does not promise arcs between theFigure 4 Average survival predicted with the model from Tai et al
normal liver NTCPs. All fractions for nVMAT and cVMAT were si
(paired, 2-tailed t test). cVMAT, coplanar volumetric modulated ar
noncoplanar volumetric modulated arc therapy; PTV, planning targetanchoring beams are optimal. Furthermore, the method
would result in arcs that require simultaneous couch and
gantry rotation and are undeliverable in the clinical mode.
Both limitations are effectively overcome using 4p static
planning, where the collision-free beam geometry solution
space is individually mapped and the beam orientations are
optimized. Therefore, even though nVMAT is currently
available and more efficient to deliver, it is not a reasonable
substitution for 4p static.
A major difference between the current study and the
previously published report of using 4p static for liver
SBRT10 is that the liver SBRT plans are generated in Eclipse
using identical dose calculation engine to ensure an unbiased
comparison. Compared with the previous study, the liver
VL>15 was further reduced by an additionalw30 cm
3 to 80
cm3. This increased normal tissue sparing is crucial for liver
SBRT because it enables escalation of the prescription dose
to the PTV without further complications from high doses to
normal tissue. Our dose escalation study showed that for the
same normal liver complication probability, prescription
doses delivered with the 4p static technique could be20 for the maximum tolerable doses yielding 1%, 5%, and 10%
gnificantly different than 4p static at the 5% significance level
c therapy; NTCP, normal tissue control probability; nVMAT,
volume.
Advances in Radiation Oncology: JanuaryeMarch 2016 Noncoplanar IMRT vs VMAT for liver SBRT 75escalated 20% higher than cVMAT plans and 14% higher
than nVMAT plans, leading to significant increases in pre-
dicted survival fractions.
Improved liver tumor motion management can be
combined with 4p static radiation therapy for additional
dosimetric gains, but the gain may be less significant. For
example, Velec et al30 showed that by reducing the PTV
volume using the mean respiratory position, the iso-
toxicity PTV dose can be escalated by 4 Gy, a moderate
number compared to the dose escalation using 4p static.
Conclusions
4p static radiation therapy using optimized nonco-
planar beams significantly reduces normal liver doses that
can facilitate safe tumor dose escalation. Despite its
clinical availability, VMAT using noncoplanar arcs is not
a viable replacement of 4p static radiation therapy for
compact dose liver SBRT.References
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